Minerva Neurosciences, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023, compared with FY 2022. This annual filing does not provide separate fourth-quarter results.
Business context
Minerva is a clinical-stage biopharmaceutical company developing CNS treatments. Its lead candidate, roluperidone, is under FDA review for negative symptoms of schizophrenia. MIN-301 for Parkinson’s disease remains deferred, and the company has no approved products or product-sales revenue.
Financial performance and position
| Metric | FY / year-end 2023 | FY / year-end 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $12.7 million | $14.6 million |
| General and administrative expense | $10.4 million | $10.6 million |
| Total operating expenses | $23.1 million | $25.2 million |
| Net loss | $30.0 million | $32.1 million |
| Net loss per share, basic and diluted | $4.61 | $6.01 |
| Cash, cash equivalents and restricted cash at year-end | $41.0 million | $36.2 million |
| Net cash used in operating activities | $14.8 million | $24.6 million |
Net loss narrowed by $2.1 million year over year. Lower R&D spending, primarily reflecting reduced NDA-preparation costs and stock compensation, was partly offset by higher non-cash interest expense on the sale of future royalties. Investment income rose to $1.4 million from $0.6 million, principally due to higher interest rates. Profit margins are not meaningful given the absence of product revenue.
At December 31, 2023, current assets were $42.0 million and current liabilities were $3.3 million. Total liabilities were $85.4 million, including an $82.0 million liability related to the sale of future seltorexant royalties; stockholders’ deficit was $28.5 million. The royalty liability is accounted for as debt financing and accretes through non-cash interest expense; the company reported no product revenue to service it. The filing states that prior term loans were repaid in 2018.
In June 2023, Minerva raised $20.0 million gross, or $19.6 million net, through a private placement of 1.425 million common shares and pre-funded warrants for 575,575 shares. No shares were sold under its at-the-market program during 2023; $22.6 million remained eligible for sale at year-end.
Material changes, outlook and risks
- Roluperidone: Following an October 2022 refusal-to-file, the FDA filed the NDA on April 27, 2023 and set a standard-review PDUFA goal date of February 26, 2024. The filing describes potential review concerns involving antipsychotic drug interactions, applicability of non-U.S. trial data to U.S. patients, efficacy evidence, and patient identification. The 2023 filing does not report the FDA’s decision after that goal date.
- Evidence was mixed across the two pivotal studies: the Phase 2b study met its primary endpoint; the Phase 3 study missed its primary intent-to-treat endpoint (p≤0.064), while a modified analysis excluding 17 patients from a site with implausible data was nominally significant (p≤0.044). The filing notes this site and analysis as part of the evidence supporting the NDA.
- A Phase 1b study of roluperidone with olanzapine began in October 2023; results were expected in Q1 2024. The company also described ongoing manufacturing scale-up and validation work.
- MIN-301 development was deferred in 2021 to focus resources on roluperidone; no development update was reported for 2023. A $15.2 million non-cash impairment was recorded in 2021.
- Janssen completed one Phase 3 seltorexant study in 2023, continued another and had discontinued a third in 2022. Any additional Royalty Pharma milestone payments depend on future clinical, regulatory and commercial milestones. The royalty liability’s estimated effective annual interest rate was 10.97% at year-end and is sensitive to assumptions about future royalties.
- Management said year-end cash should cover operating commitments for at least 12 months after the financial statements were issued, but also said further capital will be needed to fund operations and later-stage development. Additional financing may dilute shareholders or may not be available on acceptable terms; management may scale back or discontinue operations if financing cannot be obtained.
- Other key risks include clinical and regulatory failure or delay, reliance on contract manufacturers and trial vendors, limited commercialization capacity, pricing and reimbursement uncertainty, intellectual-property exposure, cybersecurity and data-privacy risks, and possible Nasdaq delisting. The company had 9 full-time employees.
Important facts for investors to verify
- FDA’s actual action on the roluperidone NDA after the February 26, 2024 PDUFA goal date, including any additional-study or labeling requirements.
- Q1 2024 results from the roluperidone–olanzapine Phase 1b study and any subsequent clinical or regulatory updates.
- Cash runway under updated spending plans, expected financing needs, and potential dilution from pre-funded warrants or the ATM program.
- Royalty Pharma liability assumptions, future non-cash interest expense, and whether Janssen’s seltorexant program achieves payment milestones.
- Roluperidone’s manufacturing-readiness status and the resources required for a potential launch; the filing provides no specific commercialization guidance or launch budget.
Audit and controls: Deloitte & Touche issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not provide an ICFR attestation.